Odyssey Health, Inc.
For the period ended Jan 31, 2026. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jan 31, 2026 · Filed Mar 12, 2026
ODYYStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended January 31, | Six Months Ended January 31, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| General and administrative expense | $181,942 | $156,593 | $485,132 | $736,020 |
| Loss from operations | (181,942) | (156,593) | (485,132) | (736,020) |
| Loss from change in fair value of Oragenics, Inc. common stock | – | – | – | (370,698) |
| Interest expense | (412,429) | (63,431) | (507,765) | (132,217) |
| Financing costs | (2,572,655) | – | (3,080,023) | – |
| Change in fair value of derivative liabilities | (424,348) | – | (1,929) | – |
| Other expense, net | (10,249) | (102) | (10,221) | (97) |
| Net loss attributable to common shareholders | $(3,601,623) | $(220,126) | $(4,085,070) | $(1,239,032) |
| Basic net loss per share | $(0.03) | $(0.00) | $(0.04) | $(0.01) |
| Diluted loss per share | $(0.03) | $(0.00) | $(0.04) | $(0.01) |
| Shares used for basic net loss per share | 107,853,763 | 104,709,763 | 106,945,198 | 104,709,763 |
| Shares used for diluted net loss per share | 107,853,763 | 104,709,763 | 106,945,198 | 104,709,763 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.